Markman M
Department of Medicine, Memorial Sloan-Kettering Cancer Center.
Oncology (Williston Park). 1987 Mar;1(1):25-30.
While the most effective treatment regimens and both short-term and long-term toxicities remain to be determined, it is not unreasonable for clinicians treating patients with minimal residual disease following cisplatin-based systemic chemotherapy for ovarian carcinoma to try cisplatin by the intraperitoneal route.
虽然最有效的治疗方案以及短期和长期毒性仍有待确定，但对于在以顺铂为基础的系统性化疗后治疗卵巢癌微小残留病患者的临床医生来说，尝试通过腹腔途径使用顺铂并非不合理。
